Once considered to act primarily through reductions in albuminuria, GLP-1RAs now have dedicated hard-endpoint evidence: in the FLOW trial, semaglutide reduced the primary composite kidney outcome ( 50% eGFR decline, kidney failure, or kidney or cardiovascular death) by 24% (hazard ratio 0.76, 95% CI 0.660.88) in type 2 diabetes and CKD and slowed eGFR decline [48, 49]
On the other hand, another theory is that the rapid weight loss caused by these agents may trigger telogen effluvium, a type of non-scarring alopecia characterized by widespread hair shedding, typically seen after metabolic stress
Patients often ask what happens if you miss a GLP-1 dose, but with patches, the issue is bigger, they dont deliver the drug at all
The metabolism of tumors in the body